fulvestrant has been researched along with metallothionein in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, J; Liang, K; Xiao, Z; Yang, L | 1 |
| Helgason, CD; Mager, DL; Nakamura, H; Romanish, MT; Wang, Y; Xue, H | 1 |
2 other study(ies) available for fulvestrant and metallothionein
| Article | Year |
|---|---|
A bipartite recombinant yeast system for the identification of subtype-selective estrogen receptor ligands.
Topics: Analysis of Variance; Biosensing Techniques; Carrier Proteins; Chromatin Immunoprecipitation; Cloning, Molecular; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogen Receptor Modulators; Estrogens; Female; Fulvestrant; Humans; Ligands; Male; Metallothionein; Recombinant Fusion Proteins; Reproducibility of Results; Saccharomyces cerevisiae; Sensitivity and Specificity; Transcriptional Activation | 2009 |
Genistein versus ICI 182, 780: an ally or enemy in metastatic progression of prostate cancer.
Topics: Animals; Antineoplastic Agents; Disease Models, Animal; Disease Progression; Estradiol; Estrogen Antagonists; Estrogen Receptor beta; Fulvestrant; Gene Expression Regulation, Neoplastic; Genistein; Humans; Male; Metallothionein; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasm Metastasis; Prostatic Neoplasms; RNA, Small Interfering; Treatment Outcome; Xenograft Model Antitumor Assays | 2013 |